Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31697438 | 0.98 | CYP1A2 (0.36) | CYP1A2EPHX2ALDH1A1MAPTTHRB | |
| SCHEMBL15130700 | 0.98 | CYP1A2 (0.36) | CYP1A2EPHX2ALDH1A1MAPTTHRB | |
| SCHEMBL29167439 | 0.98 | CYP1A2 (0.36) | CYP1A2EPHX2ALDH1A1MAPTTHRB | |
| SCHEMBL25191851 | 0.98 | CYP1A2 (0.36) | CYP1A2EPHX2ALDH1A1MAPTTHRB | |
| SCHEMBL22295484 | 0.93 | EPHX2 (0.39) | CYP1A2EPHX2ALDH1A1MAPTTHRB | |
| SCHEMBL22295492 | 0.93 | EPHX2 (0.39) | CYP1A2EPHX2ALDH1A1MAPTTHRB | |
| SCHEMBL22276632 | 0.91 | EPHX2 (0.38) | CYP1A2EPHX2ALDH1A1MAPTTHRB | |
| SCHEMBL16329744 | 0.89 | CYP1A2 (0.32) | CYP1A2EPHX2STING1 | |
| SCHEMBL1668810 | 0.89 | STING1 (0.34) | CYP1A2EPHX2STING1HDAC8HDAC1 | |
| SCHEMBL31250921 | 0.87 | CYP1A2 (0.40) | CYP1A2EPHX2ALDH1A1THRBSTING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018583-A1 | METHOD FOR ANALYZING HIGHER-ORDER STRUCTURE OF RNA | XFOREST THERAPEUTICS CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| US-20230382886-A1 | CONJUGATED TLR7 AND NOD2 AGONISTS | UNIVERZA V LJUBLJANI (SI) | 2023-11-30 | — | — | US | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
| WO-2022148459-A1 | CLASS OF NOVEL SMAD3 PROTEIN DEGRADERS AND APPLICATION THEREOF | 和径医药科技（上海）有限公司 | 2022-07-14 | — | — | WO | disclosed |
| US-10450310-B2 | Bifunctional molecules for degradation of EGFR and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-9839687-B2 | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule | SUZHOU M-CONJ BIOTECH CO., LTD. (CN) | 2017-12-12 | — | — | US | disclosed |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| US-20160320399-A1 | MACROCYCLIC HOPO CHELATORS | LUMIPHORE, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9273059-B2 | Macrocyclic HOPO chelators | LUMIPHORE, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20120214253-A1 | MACROCYCLIC HOPO CHELATORS | LUMIPHORE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120077781-A1 | FLAVIN DERIVATIVES | GADWOOD ROBERT (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018583-A1 | METHOD FOR ANALYZING HIGHER-ORDER STRUCTURE OF RNA | NSUN2, NSUN3, FBL | CYP1A2 4782/4885EPHX2 3041/4885ALDH1A1 3488/4885 |
| US-20230382886-A1 | CONJUGATED TLR7 AND NOD2 AGONISTS | NOD2, TLR7, TLR9 | CYP1A2 2475/4885EPHX2 2943/4885ALDH1A1 4574/4885 |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | CYP1A2 4343/4885EPHX2 3168/4885ALDH1A1 1330/4885 |
| US-20160320399-A1 | MACROCYCLIC HOPO CHELATORS | PHPT1, SSB, CD69 | CYP1A2 4852/4885EPHX2 3048/4885ALDH1A1 4846/4885 |
| US-20120214253-A1 | MACROCYCLIC HOPO CHELATORS | PHPT1, SSB, CD69 | CYP1A2 4852/4885EPHX2 3048/4885ALDH1A1 4846/4885 |
| US-10450310-B2 | Bifunctional molecules for degradation of EGFR and methods of use | EGFR, ERBB2, ERBB3 | CYP1A2 3906/4885EPHX2 1013/4885ALDH1A1 2376/4885 |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | AURKC, AURKA, AURKB | CYP1A2 4376/4885EPHX2 3217/4885ALDH1A1 1924/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | CYP1A2 4692/4885EPHX2 4580/4885ALDH1A1 2528/4885 |
| US-20120077781-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | CYP1A2 465/4885EPHX2 1099/4885ALDH1A1 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.